Literature DB >> 1592288

Resection of pulmonary metastases from uterine sarcomas.

C Levenback1, S C Rubin, P M McCormack, W J Hoskins, E N Atkinson, J L Lewis.   

Abstract

Long-term survival following resection of pulmonary metastases has been well documented. Variables that are believed to have an effect on survival are site of primary tumor, number and size of metastases, resectability, laterality of the metastases, doubling time, and disease-free interval. Published information regarding resection of pulmonary metastases in patients with gynecologic primary tumors is limited. We reviewed 45 patients whose pulmonary metastases from uterine sarcomas were resected at Memorial Sloan Kettering Cancer Center between 1960 and 1989. All cases met carefully defined criteria at time of thoracotomy: prior hysterectomy for uterine sarcoma, no extrathoracic tumor, known disease thought to be resectable, histology consistent with uterine sarcoma, and no medical contraindication to thoracotomy. Seventy-one percent had unilateral lesions, fifty-one percent had one lesion, and seventy percent had nodules greater than 2 cm. Thirty-six percent had incomplete resection at thoracotomy. Actuarial 5- and 10-year survival from hysterectomy for uterine sarcoma was 65 and 50%, respectively, with a mean follow-up of 89 months. Five- and ten-year survival from resection of pulmonary metastases was 43 and 35%, respectively, with a mean follow-up of 25 months. Unilateral vs bilateral disease was a significant predictor of survival after pulmonary resection (P = 0.02). Metastases size, number of metastases, disease-free interval, and patient age were not significant. Among this carefully selected group of patients undergoing resection of pulmonary metastases from uterine sarcomas, long-term survival was achieved by a substantial proportion of patients. No single risk factor is sufficiently accurate to exclude an individual patient from consideration for pulmonary resection.

Entities:  

Mesh:

Year:  1992        PMID: 1592288     DOI: 10.1016/0090-8258(92)90286-r

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

Review 1.  A review of treatment of uterine leiomyosarcomas.

Authors:  Nicholas Reed
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

2.  Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.

Authors:  Paulina Cybulska; Vasileios Sioulas; Theofano Orfanelli; Oliver Zivanovic; Jennifer J Mueller; Vance A Broach; Kara C Long Roche; Yukio Sonoda; Martee L Hensley; Roisin E O'Cearbhaill; Dennis S Chi; Kaled M Alektiar; Nadeem R Abu-Rustum; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2019-06-12       Impact factor: 5.482

3.  Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas.

Authors:  Kenichi Nakamura; Hiroaki Kajiyama; Fumi Utsumi; Shiro Suzuki; Kaoru Niimi; Ryuichiro Sekiya; Jun Sakata; Eiko Yamamoto; Kiyosumi Shibata; Fumitaka Kikkawa
Journal:  Mol Clin Oncol       Date:  2018-01-19

4.  [Uterine sarcoma treatment].

Authors:  G Köhler
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

Review 5.  Pulmonary metastasectomy in uterine malignancy: outcomes and prognostic factors.

Authors:  Rocco Bilancia; Marco Nardini; David Waller
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 6.  Uterine/female genital sarcomas.

Authors:  M L Hensley
Journal:  Curr Treat Options Oncol       Date:  2000-06

7.  Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Authors:  Martee L Hensley; Michael W Sill; Dennis R Scribner; Jubilee Brown; Robert L Debernardo; Ellen M Hartenbach; Carolyn K McCourt; James R Bosscher; Paola A Gehrig
Journal:  Gynecol Oncol       Date:  2009-10-06       Impact factor: 5.482

8.  Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).

Authors:  D Denschlag; F C Thiel; S Ackermann; P Harter; I Juhasz-Boess; P Mallmann; H-G Strauss; U Ulrich; L-C Horn; D Schmidt; D Vordermark; T Vogl; P Reichardt; P Gaß; M Gebhardt; M W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-10       Impact factor: 2.915

9.  Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Authors:  Martee L Hensley; John A Blessing; Koen Degeest; Ovadia Abulafia; Peter G Rose; Howard D Homesley
Journal:  Gynecol Oncol       Date:  2008-04-18       Impact factor: 5.482

10.  Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019).

Authors:  Dominik Denschlag; Sven Ackermann; Marco Johannes Battista; Wolfgang Cremer; Gerlinde Egerer; Markus Follmann; Heidemarie Haas; Philipp Harter; Simone Hettmer; Lars-Christian Horn; Ingolf Juhasz-Boess; Karin Kast; Günter Köhler; Thomas Kröncke; Katja Lindel; Peter Mallmann; Regine Meyer-Steinacker; Alexander Mustea; Edgar Petru; Peter Reichardt; Dietmar Schmidt; Hans-Georg Strauss; Clemens Tempfer; Falk Thiel; Uwe Ulrich; Thomas Vogl; Dirk Vordermark; Paul Gass; Matthias W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-10-22       Impact factor: 2.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.